Amazon appears to be entering pharmacy business

John Gregory | | Health Exec | Precision Medicine

Tech giant Amazon has reportedly received approval to become a wholesale pharmacy distributor in at least a dozen states, according to the St. Louis Post-Dispatch.

The licenses have been quietly granted over the past year by state pharmaceutical boards in 12 states: Nevada, Arizona, North Dakota, Louisiana, Alabama, New Jersey, Michigan, Connecticut, Idaho, New Hampshire, Oregon and Tennessee. An application is currently pending in Maine.

Amazon declined to comment on “rumors or speculation.” Leerink Partners analyst Ana Gupte told the Post-Dispatch the licenses “strengthens our conviction on the likely entry into the drug supply chain. It is still not clear if (Amazon) will pursue a buy or partner with an existing (pharmacy benefit manager) or build such capabilities from within.”

The company would still need to obtain an additional pharmacy license to begin shipping drugs or devices to consumers.

Read more at the link below:

Amazon gains wholesale pharmacy licenses in multiple states

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

AI in Healthcare
4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Design by Adaptive Theme
Trimed Popup
Trimed Popup